Management and members of the board of directors have subscribed for shares in Active Biotech’s ongoing rights issue
November 29, 2023
Front Page
Preclinical data of tasquinimod in myelofibrosis awarded oral presentation at ASH 2023
November 2, 2023
Active Biotech presentation at Aktiespararnas “Aktiedag Lund”, October 9, 2023 (in Swedish)
October 10, 2023
Clinical safety and preclinical ocular biodistribution for laquinimod eye drops presented at the IOIS meeting available at Active Biotech’s website
September 13, 2023
Tasquinimod successfully completes dose optimization in patients with multiple myeloma and advances into the pre-planned expansion cohort
September 11, 2023
Active Biotech enters into clinical trial collaboration agreement for a clinical study with tasquinimod in myelofibrosis
August 1, 2023
Safety and ocular biodistribution support development of laquinimod eye drops for inflammatory eye disorders
May 30, 2023
New preclinical data on the antifibrotic effects of tasquinimod in myelofibrosis to be presented at EHA 2023
May 12, 2023
NeoTX poster from the American Association for Cancer Research (AACR) Annual Meeting is now available
April 19, 2023
Safety and preliminary activity of naptumomab in combination with durvalumab presented at AACR 2023
April 19, 2023
Two recent publications describe the mechanisms by which tasquinimod can act as a potential treatment alternative in multiple myeloma
March 16, 2023
Active Biotech: Infocus interview with CEO Helén Tuvesson at Redeye Life Science Day 2022 (in Swedish)
November 29, 2022
Active Biotech further strengthens the patent protection for laquinimod in eye disorders with a granted patent in US
October 24, 2022
Helén Tuvesson, CEO, and Erik Vahtola, CMO, will attend Bio-Europe 2022, meet us October 24-26, in Leipzig, Germany.
October 18, 2022